Parkinson Disease, Secondary
"Parkinson Disease, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Descriptor ID |
D010302
|
| MeSH Number(s) |
C10.228.140.079.862.800 C10.228.662.600.700
|
| Concept/Terms |
Parkinson Disease, Secondary- Parkinson Disease, Secondary
- Secondary Parkinson Disease
- Symptomatic Parkinson Disease
- Parkinsonism, Symptomatic
- Symptomatic Parkinsonism
- Secondary Parkinsonism
- Parkinson Disease, Symptomatic
- Parkinsonism, Secondary
|
Below are MeSH descriptors whose meaning is more general than "Parkinson Disease, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Parkinson Disease, Secondary".
This graph shows the total number of publications written about "Parkinson Disease, Secondary" by people in this website by year, and whether "Parkinson Disease, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Parkinson Disease, Secondary" by people in Profiles.
-
Cascading from SARS-CoV-2 to Parkinson's Disease through Protein-Protein Interactions. Viruses. 2021 05 12; 13(5).
-
Parkinson's disease following COVID-19: causal link or chance occurrence? J Transl Med. 2020 12 29; 18(1):493.
-
Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease. Biochem Biophys Res Commun. 2019 05 28; 513(2):306-312.
-
Eplingiella fruticosa leaf essential oil complexed with ß-cyclodextrin produces a superior neuroprotective and behavioral profile in a mice model of Parkinson's disease. Food Chem Toxicol. 2019 Feb; 124:17-29.
-
Pathophysiological mechanisms linking F-box only protein 7 (FBXO7) and Parkinson's disease (PD). Mutat Res Rev Mutat Res. 2018 Oct - Dec; 778:72-78.
-
Neutral Sphingomyelinase Behaviour in Hippocampus Neuroinflammation of MPTP-Induced Mouse Model of Parkinson's Disease and in Embryonic Hippocampal Cells. Mediators Inflamm. 2017; 2017:2470950.
-
Secondary parkinsonism in a patient of psychogenic polydipsia. BMJ Case Rep. 2017 Apr 26; 2017.
-
Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy. J Clin Invest. 2017 Feb 01; 127(2):720-734.
-
Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases--a mechanistic approach. Toxicol Lett. 2014 Oct 15; 230(2):85-103.
-
Apomorphine and levodopa challenge in patients with a focal midbrain lesion. Mov Disord. 1999 Mar; 14(2):269-75.